Analyst consensus rating
INmune Bio Analyst Rating: Strong Buy
INMB is rated Strong Buy by 4 analysts with a $7.00 target. As of 2026-08-27.
Direct answer
INmune Bio's consensus rating is Strong Buy.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $7.00.
Forecast evidence checked August 27, 2026.
Get free INmune Bio email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.45
- Average price target
- $7.00
- High price target
- $9.00
- Low price target
- $4.00
- Low target gap
- +63.6%
- Target upside
- +186.3%
- High target gap
- +268.1%
- Target range width
- 204.5%
- Consensus rating
- Strong Buy
- Analysts
- 4
- Evidence date
- August 27, 2026
- Valid through
- September 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for INmune Bio?
INmune Bio has a verified Strong Buy consensus. The same dataset has an average price target of $7.00.
How far are INmune Bio's low and high targets from the recorded price?
The low target implies +63.6%, while the high target implies +268.1%.
How many analysts are included in INmune Bio's consensus?
The verified consensus includes 4 analysts.
How is INmune Bio's target upside or downside calculated?
The average target of $7.00 is divided by the recorded price of $2.45, then one is subtracted to produce +186.3%. This does not guarantee a future return.
When was INmune Bio's analyst forecast verified?
The data was verified on 2026-08-27. The dataset is valid through 2026-09-03.